Skip to main content

Table 1 Baseline characteristics of CHB-related compensated cirrhosis

From: Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study

 

ADV-containing

Non-ADV-containing

p-value

(n=127)

(n=115)

Age, (mean ± SD)

50 ± 12

50 ± 10

0.62

Gender

  

0.28

 Male

114 (89.8%)

98 (85.2%)

 

 Female

13 (12.4%)

17 (9.7%)

 

HBV DNA (log10 copy/mL, mean ± SD)

3.93 ± 1.31

3.88 ± 1.18

0.76

HBeAg

  

0.92

 Positive

92 (72.4%)

84 (73.0%)

 

 Negative

35 (27.6%)

31 (27.0%)

 

ALT (U/L, mean ± SD)

98.3 ± 23.6

96.3 ± 24.4

0.34

Total bilirubin (μmol/L), median (range)

16.1 (5.7-65.0)

14.4 (5.5-39.8)

0.11

ALB (g/L), median (range)

4.5 (3.8-6.3)

4.0 (2.9-6.1)

0.09

AFP, ng/mL, median (range)

4.91 (1.21-28)

5.41 (1.16-31)

0.08

PLT, 10^9/L, median (range)

186.31 (97-231)

178.44 (103-241)

0.13

Child-Pugh score

  

0.87

 A

122 (96.1%)

110 (95.6%)

 

 B

5 (3.9%)

5 (4.4%)

 
  1. HBeAg hepatitis B e antigen, AFP α-fetoprotein, ALB albumin, PLT platelet, SD standard deviation